Latest News

  • INNOVATION

    25 Feb 2026

    Can AI Rethink How New Drugs Are Found?

  • PARTNERSHIPS

    24 Feb 2026

    Lilly Deepens AI Push in Obesity Drug Race

  • INVESTMENT

    23 Feb 2026

    Another Shot in the Obesity Gold Rush

  • MARKET TRENDS

    19 Feb 2026

    Precision Medicine Rises as Biomarkers Drive Change

Pfizer Steps Up Obesity Push With Metsera Deal

Pfizer corporate logo displayed outside office building

PARTNERSHIPS

17 Feb 2026

US drugmaker agrees multibillion-dollar acquisition to bolster metabolic pipeline and challenge leaders in weight-loss therapies

Wegovy vial and syringe beside a stylized model of metabolic liver and fat cells.

REGULATORY

20 Nov 2025

FDA Nod for Metabolic-Liver Therapy Reshapes Treatment Horizon

FDA expands Wegovy to MASH, potentially expanding the metabolic liver disease market and influencing developer strategy

Red-yellow capsules on a high-tech circuit board symbolizing oral metabolic drug innovation.

PARTNERSHIPS

18 Nov 2025

New Partnership Accelerates Push for Oral Metabolic Breakthroughs

Deep Apple Therapeutics and Novo Nordisk team on a non incretin oral target, stirring new momentum in metabolic research

Novo Nordisk headquarters building symbolizing MASH treatment innovation

INNOVATION

14 Nov 2025

Novo Sparks a New Fight to Fix MASH

Novo’s Akero buy raises the stakes in MASH as investors await key fibrosis data

Close-up illustration of an RNA strand in a biomedical research concept.

INSIGHTS

10 Nov 2025

Lilly’s New RNAi Partner Aims for Two Doses a Year

Eli Lilly and SanegeneBio team up to create long-acting RNAi drugs for obesity and diabetes

Two Victoza liraglutide injection pens displayed on a light wooden surface.

MARKET TRENDS

2 Sep 2025

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

Teva's launch of a Saxenda copy shakes up pricing power, forcing Novo and Lilly to rethink access and affordability.

White Novo Nordisk flags wave on tall poles against a cloudy sky, representing the company’s global presence.

PARTNERSHIPS

29 Aug 2025

Novo Nordisk Bets $550M on RNA's Next Act

Novo Nordisk partners with Replicate Bioscience to develop RNA-based obesity therapies, aiming to evolve beyond current GLP-1 blockbusters...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.